Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Aethlon Medical Inc

NASDAQ: AEMD · Industrial Applications and Services · 8 alerts · CIK 882291

Share price
$5.01Close, Nov 16
Market cap
$8.05M
Shares outstanding
1.61MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Aethlon Medical Inc filings on SEC EDGAR ↗

4:37 PM ET 8-K
M&A Deal

Aethlon Medical M&A Deal with North Immunology, Inc.

Aethlon Medical provided a status update on its pending merger with North Immunology, Inc., originally announced on September 17, 2026. The filing includes an updated investor presentation that North Immunology will use in meetings with investors regarding the transaction and a concurrent private placement.

Counterparty
North Immunology, Inc.
4:32 PM ET 10-Q
Financial Results

Aethlon Medical Q2 2026 Results: Net Loss of $2.62M, Loss Widens

Aethlon Medical reported a net loss of $4.17 million for the six months ended September 30, 2026, compared to $3.25 million in the prior year period, driven largely by increased professional fees. The company is currently pursuing a merger with North Immunology, Inc. and has raised capital through common stock issuances to maintain a cash balance of approximately $6.49 million.

Key figure
Net loss $2.62M
4:31 PM ET 8-K
Financial Results

Aethlon Medical Financial Results

Aethlon Medical reported financial results for its fiscal second quarter ended September 30, 2026, highlighting a cash position of $6.5 million and a 77.2% increase in operating expenses due to merger-related professional fees. The company is currently progressing through a definitive merger agreement with North Immunology, Inc., which includes a contingent value right (CVR) for existing shareholders related to the legacy Hemopurifier business.

“We advanced our clinical program during the quarter. We treated the second participant in the third and final dosing cohort of our Phase 1 oncology study in Australia. We have treated eight patients across the three dosing cohorts to date and continue to pursue enrollment of one additional patient.”

James Frakes, CEO and CFO
4:16 PM ET 8-K
Other 8-K Filing

Aethlon Medical Other 8-K Filing

Aethlon Medical filed an amendment to its Articles of Incorporation to increase the number of authorized shares of common stock from 20,000,000 to 200,000,000. The amendment was approved by stockholders at the 2026 Annual Meeting and became effective on October 7, 2026. This action increases the company's capacity for future equity issuances, though no shares were issued in this specific filing.

4:11 PM ET 8-K/A
Shareholder Meeting

Aethlon Medical Shareholder Meeting

Aethlon Medical filed an amendment to its 2026 Annual Meeting results to clarify that Proposal No. 7, which sought to authorize 20 million shares of preferred stock, was not approved by stockholders. Although the proposal received a majority of votes cast, it failed to meet the required threshold of a majority of all outstanding shares. As a result, the company's Articles of Incorporation will not be amended to authorize the new class of preferred stock.

5:24 PM ET 8-K
Shareholder Meeting

Aethlon Medical Shareholder Meeting

Aethlon Medical held its Annual Meeting of Stockholders on October 1, 2026, where shareholders elected five directors and ratified Haskell & White LLP as the independent auditor. Stockholders also approved an amendment to the 2020 Equity Incentive Plan to increase the authorized share pool by 100,000 shares and approved the potential issuance of shares related to warrants from a July 2026 offering.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.